Filing Details
- Accession Number:
- 0001209191-20-001176
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-01-03 17:09:21
- Reporting Period:
- 2019-12-31
- Accepted Time:
- 2020-01-03 17:09:21
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1107421 | Ziopharm Oncology Inc | ZIOP | Pharmaceutical Preparations (2834) | 841475642 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1429559 | G Kevin Lafond | C/O Ziopharm Oncology, Inc. One First Avenue, Parris Bldg 34 Boston MA 02129 | Svp, Treasurer & Cao | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2020-01-02 | 21,570 | $4.55 | 63,985 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (right to buy) | Acquisiton | 2019-12-31 | 48,000 | $0.00 | 48,000 | $4.72 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
48,000 | 2029-12-31 | No | 4 | A | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholdingtax obligations upon the vesting of restricted stock grants.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.46 to $4.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2019.